Clinical Trial Update: Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing reduced prasugrel dosing and polymer technology in acute coronary syndrome patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• PRASUGREL (prasugrel)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Acute Coronary Syndrome | Phase 4 | Status: COMPLETED